Ascelia Pharma AB (publ) Cash Flow-to-Debt Ratio
Ascelia Pharma AB (publ) cash flow-to-debt ratio. Ascelia Pharma AB (publ) (ACE) has a Cash Flow-to-Debt Ratio of -0.71x as of September 2025, meaning its operating cash flow of Skr-15.66 Million could theoretically repay -1% of its total liabilities (Skr22.01 Million) in one year. See Ascelia Pharma AB (publ) (ACE) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Ascelia Pharma AB (publ) (2017–2024)
Cash flow-to-debt ratio of Ascelia Pharma AB (publ) from 2017 to 2024. Historical debt coverage capacity for Ascelia Pharma AB (publ) across 8 annual periods. Also explore how fast is Ascelia Pharma AB (publ) growing its equity to track the company's year-over-year net asset growth rate.
Ascelia Pharma AB (publ) Cash Flow-to-Debt Ratio by Year (2017–2024)
Ascelia Pharma AB (publ) cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Ascelia Pharma AB (publ). For the full cash flow conversion analysis, see how efficiently does Ascelia Pharma AB (publ) generate cash.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.01x | Skr-62.84 Million | Skr61.98 Million | ▲ +89.8% |
| 2023 | -9.95x | Skr-126.79 Million | Skr12.74 Million | ▼ -199.5% |
| 2022 | -3.32x | Skr-125.26 Million | Skr37.71 Million | ▲ +26.9% |
| 2021 | -4.54x | Skr-116.56 Million | Skr25.66 Million | ▼ -2.6% |
| 2020 | -4.43x | Skr-85.53 Million | Skr19.32 Million | ▼ -57.9% |
| 2019 | -2.80x | Skr-36.92 Million | Skr13.16 Million | ▼ -4.9% |
| 2018 | -2.67x | Skr-30.33 Million | Skr11.35 Million | ▲ +43.6% |
| 2017 | -4.74x | Skr-20.96 Million | Skr4.42 Million | — |